CytomX Therapeutics Announces New Employment Inducement Grants

Core Insights - CytomX Therapeutics, Inc. granted options to purchase 130,000 shares of common stock at an exercise price of $1.96 on May 15, 2024, to two new employees [1][2] Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY® therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-904, CX-2051, and CX-801, targeting various cancer types through innovative mechanisms [3] Pipeline Details - CX-904 is a bispecific antibody targeting EGFR on tumor cells and CD3 on T cells, partnered with Amgen for global co-development [3] - CX-2051 is an ADC directed at EpCAM, with potential applications across multiple epithelial cancers, discovered in collaboration with Immunogen [3] - CX-801 is a masked interferon alpha-2b PROBODY® cytokine with potential in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading oncology companies including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]